In Opthea’s SEC filing related to its planned IPO, the company has also announced plans to develop a co-formulation of OPT-302 with an approved and/or biosimilar anti-VEGF-A therapy. It is expected that an IND will be filed next year.
http://archive.fast-edgar.com/20200924/A82LC22EZZ2R82Z222J92WYPJ8SDZZ22X222/
Ann: Opthea Files Registration Statement for Proposed US IPO, page-8
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
78.0¢ |
Change
-0.010(1.27%) |
Mkt cap ! $960.2M | |||
| Open | High | Low | Value | Volume |
| 79.0¢ | 79.5¢ | 74.5¢ | $2.420M | 3.109M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 77.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 78.0¢ | 77447 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |